



PRESS RELEASE

New Directors elected at Nobel Biocare

At today's extraordinary shareholders' meeting, Ms Heliane Canepa and Dr Ernst Thomke were *elected* as directors. Lars Ingelmark had decided to resign from the board. The number of directors has thus been increased from eight to nine.

Directors Ms Heliane Canepa and Dr Ernst Thomke were proposed by the Swiss medtech fund BB Medtech AG which is listed in Switzerland and on Neuer Markt in Germany. Shareholders representing approximately 20% of the outstanding shares and votes supported the nomination.

The Nobel Biocare board of directors represents in depth industrial knowledge and vast international experience that is in line with Nobel Biocare's international business orientation and owner structure.

Ms Heliane Canepa, Switzerland, is the former CEO of the cardiology company Schneider and is currently a board member of BB Medtech AG, Migros, Phonak Holding Ltd, Switzerland, and Intratherapeutics, USA. *Dr Ernst Thomke*, Switzerland, has vast experience of the medtech sector and is the Chairman of BB Medtech AG, BB Biotech AG and Metaux Précieux SA METALOR, Switzerland. He is also a board member of Phonak Holding Ltd, Switzerland.

Other board members elected by the Annual General Meeting are:

Kenneth A Darienzo, USA, former CEO of Steri-Oss Inc., *Jan Ekberg*, former CEO and Chairman of Pharmacia Inc., *Roger Holtback*, CEO of Bure Equity AB, *Jan Kvarnström*, senior adviser to companies including the venture capital company 3i Plc. and former CEO of Esselte AB and Securum AB, *Håkan Larsson*, Chairman of Schenker AG, Germany, *T. Michael Long*, USA, Partner in Brown Brothers Harriman & Co, Private Bankers, New York and *Jack Forsgren*, CEO of Nobel Biocare AB.

Gothenburg, December 11, 2000

NOBEL BIO CARE AB

For more information, please contact:

Jack Forsgren, CEO, telephone +46 31 81 88 58, or Jan H Johansson, General Counsel, telephone +46 31 81 88 29, Nobel Biocare AB.

Nobel Biocare is an innovative, medical devices company, whose core business comprises dental implants and dental prosthetics. The company's product systems for dental implants, Brånemark System® and Steri-Oss®, are world leaders and have a global market share of around 40%.

The company's other product line, Procera®, is a unique, IT-based process for the industrial production of dental prosthetics. The system has been launched very successfully in 22 countries.

Nobel Biocare has around 1,190 employees and, in 1999, turnover totaled SEK 1,738 million. The company's headquarters are located in Gothenburg, Sweden, while production takes place in Sweden and the USA. Nobel Biocare has its own sales companies in 25 countries.

Nobel Biocare AB, Box 5190, SE-401 26 Gothenburg, Sweden

Telephone +46 31 81 88 00. Fax +46 31 16 31 52

e-mail: investor.relations@nobelbiocare.se

www.nobelbiocare.com